Small molecule · Modulator
HT-001 is a topical gel with potential immunomodulatory activity, applied to the skin, scalp and nails. It is intended to inhibit the recruitment and activation of immune cells and the expression of inflammatory mediators triggered by EGFR signaling blockade. It is being studied for skin toxicity caused by EGFR inhibitor cancer therapy, including acneiform eruption, xerosis cutis and paronychia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05639933 | Phase 2 | Acneiform Eruption Due to Chemical | Recruiting | ICLR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acneiform Eruption Due to ChemicalParonychiaXerosis Cutis